Effectiveness of Pathways on Improving Quality of Care

John E. Hennessy, CMPE

Current Issue

Health Inequities in America

David B. Nash, MD, MBA

September 2017 Vol 10, No 6 - Editorial

Costs and Effectiveness of Mindfulness-Based Art Therapy versus Standard Breast Cancer Support Group for Women with Cancer

Katherine M. Prioli, BS, Laura T. Pizzi, PharmD, MPH, Kathryn M. Kash, PhD, Andrew B. Newberg, MD, Anna Marie Morlino, PharmD, Michael Matthews, BS, Daniel A. Monti, MD

September 2017 Vol 10, No 6 - Business, Original Research

Stakeholder Perspective

Creative Therapeutic Activities and Support Groups Benefit All Those Involved in Cancer Care

by Linda Bily, MA, CSA, OPN-CG

Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide

Ajay S. Behl, PhD, Lorie A. Ellis, PhD, Dominic Pilon, MA, Yongling Xiao, PhD

September 2017 Vol 10, No 6 - Clinical, Original Research

Stakeholder Perspective

A First Step Toward Improving the Complex Approach to Metastatic Prostate Cancer Management

by Gary M. Owens, MD

The Relative Burden of Menopausal and Postmenopausal Symptoms versus Other Major Conditions: A Retrospective Analysis of the Medical Expenditure Panel Survey Data

Annlouise R. Assaf, PhD, Andrew G. Bushmakin, MS, Nina Joyce, PhD, Michael J. Louie, MD, MPH, MSc, Michael Flores, MPH, Margaret Moffatt, MPH

September 2017 Vol 10, No 6 - Clinical, Original Research

Stakeholder Perspective

Hormone Therapy Remains Effective for Treating Menopausal Symptoms, May Save Overall Costs

by JoAnn V. Pinkerton, MD, FACOG, NCMP

Conference Correspondent

Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent

Most Popular Articles

Budget Impact of a Comprehensive Nutrition-Focused Quality Improvement Program for Malnourished Hospitalized Patients

Suela Sulo, PhD, Josh Feldstein, BA, Jamie Partridge, PhD, MBA, Bjoern Schwander, MS, RN, Krishnan Sriram, MD, Wm. Thomas Summerfelt, PhD

July 2017 Vol 10, No 5 - Business, Original Research

In Chronic Myeloid Leukemia, Selection of Tyrosine Kinase Inhibitors Depends on Variables Other Than Survival

Wayne Kuznar

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights - Leukemia

Value-Based Perspectives on the Management of Allergic Rhinitis

Eli O. Meltzer, MD, Don A. Bukstein, MD, Paul M. Hamrah, MS, PharmD, Nikkia Scott, PharmD, John A. Welz, MPH

Supplements - Value-Based Care

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer

Web Exclusives - FDA News & Updates, Web Exclusive

Kevzara (Sarilumab): A Novel IL-6 Receptor Antagonist for Rheumatoid Arthritis

Supplements - Rx Profiler

Web Exclusives

Neratinib First Extended Adjuvant Treatment for Patients with Early-Stage, HER2-Positive Breast Cancer

HER2-positive breast cancers are aggressive tumors and can spread to other parts of the body, making adjuvant therapy an important part of the treatment plan.